抗血小板药物个体化治疗对ACS患者急诊PCI术后发生终点事件的影响

Effects of individualized treatment of antiplatelet drug on end-point events in patients with ACS after emergency PCI

目的:探究抗血小板药物个体化治疗对ACS患者急诊PCI术后发生终点事件的影响。方法:将于我院行PCI的202例ACS患者分为两组,一组行常规抗血小板双联药物治疗,一组行抗血小板药物个体化治疗。比较术后6个月内两组终点事件、药物不良反应发生情况。结果:术后6个月内,观察组终点事件发生率显著低于对照组(P<0.05);两组药物不良反应发生情况无显著性差异(P>0.05)。结论:抗血小板药物个体化治疗利于预防ACS患者PCI术后终点事件。

Objective:To explore the effects of individualized treatment of antiplatelet drug on end-point events in patients with ACS after PCI.Methods:A total of 202 patients with ACS who were treated with PCI in our hospital were divided into two groups.One group was treated with conventional antiplatelet dual drug therapy,and the other group was given individualized treatment of antiplatelet drug.The occurrence of end-point events and adverse drug reactions were compared between the two groups within 6 months after surgery.Results:Within 6 months after surgery,the incidence rates of end-point events in observation group were significantly lower than those in control group(P<0.05).There were no significant differences in the occurrence of adverse drug reactions between the two groups(P>0.05).Conclusion:Individualized treatment of antiplatelet drug can help prevent the end-point events in patients with ACS after PCI.